Compare · BLFS vs TMDX
BLFS vs TMDX
Side-by-side comparison of BioLife Solutions Inc. (BLFS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLFS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.56B, about 1.8x BLFS ($1.42B).
- Over the past year, BLFS is up 40.2% and TMDX is down 28.6% - BLFS leads by 68.7 points.
- TMDX has been more active in the news (4 items in the past 4 weeks vs 3 for BLFS).
- TMDX has more recent analyst coverage (18 ratings vs 8 for BLFS).
- Company
- BioLife Solutions Inc.
- TransMedics Group Inc.
- Price
- $29.11-3.83%
- $74.01-2.55%
- Market cap
- $1.42B
- $2.56B
- 1M return
- +10.60%
- -2.15%
- 1Y return
- +40.15%
- -28.55%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 3
- 4
- Recent ratings
- 8
- 18
BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest BLFS
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 844 shares, decreasing direct ownership by 0.39% to 213,249 units (SEC Form 4) (withholding obligation)
- EVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 516 shares, decreasing direct ownership by 0.13% to 388,460 units (SEC Form 4) (for tax liability)
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 293 shares, decreasing direct ownership by 0.18% to 162,649 units (SEC Form 4) to cover taxes
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 470 shares, decreasing direct ownership by 0.29% to 162,942 units (SEC Form 4) (tax liability)
- Chief Technology Officer Werner Sean covered exercise/tax liability with 420 shares, decreasing direct ownership by 0.87% to 47,831 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 937 shares, decreasing direct ownership by 0.44% to 214,093 units (SEC Form 4) to cover taxes
- EVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 564 shares, decreasing direct ownership by 0.14% to 388,976 units (SEC Form 4) to cover taxes
- President and CEO De Greef Roderick covered exercise/tax liability with 2,775 shares, decreasing direct ownership by 0.38% to 730,971 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 1,026 shares, decreasing direct ownership by 0.47% to 215,030 units (SEC Form 4) (withholding obligation)
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 356 shares, decreasing direct ownership by 0.22% to 163,412 units (SEC Form 4) (tax withholding)
Latest TMDX
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)